Phase 1 N=41 Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
Diabetes Mellitus, Type 2
Primary: Linagliptin: AUC_τ,ss — 194 nmol*h/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 Days
Healthy
Primary: AUCτ Over a Dosing Interval (τ = 12 Hours) on Day 14 — 12090.998; 23472.1329; 30005.781; 50354.938 ng*h/mL
Phase 1 N=18 A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)
Type 2 Diabetes Mellitus
Primary: Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations — 6.00; 4.09; 7.22; 1.55 picomolar
Phase 1 N=16 Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: Brain NK1-receptor Occupancy at 24 Hours Post Dose — 100.40; 100.20 Percent of occupancy
Phase 1 N=42 A Bioequivalence (BE) Study in Healthy Subjects
Attention Deficit Hyperactivity Disorder
Primary: Maximum Observed Plasma Concentration (Cmax) — 456; 483 nanogram per millileter (ng/mL)
Phase 1 N=6 Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) — 109.400 ng/mL
Phase 1 N=16 Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
End-stage Renal Disease · Renal Failure Chronic Requiring Hemodialysis
Primary: Evaluation of Area Under the Curve From Time 0 to Infinity — 1692; 2708 hr*ug/mL
Phase 1 N=27 Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
Type 2 Diabetes Mellitus
Primary: Observed Maximum Plasma Concentration (Cmax) of Saxagliptin, Tablets and Fixed-dose Combination (FDC), Administered to Participants in the Fasted and Fed States — 10.54…
Phase 1 N=14 A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
Healthy
Primary: Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞][dn]) — 21.36; 9.28 ng*hr/mL/mg
Phase 1 N=36 Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0 - ∞]) — 2890.0; 2665.0; 2887.0; 2475.0 ng*hr/mL
Phase 1 N=15 Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 1260.00; 3986.00 ng*hr/mL
Phase 1 N=15 Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 2192.00; 397.20 ng*hr/mL
Phase 1 N=24 Relative Drug Exposures Of Two Formulations of PF-02341066
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 2804.5; 2597.3 ng*hr/mL
Phase 1 N=64 Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
Staphylococcal Infections
Primary: Number of Participants With a Positive Immune Response, Defined as a Change in Antibody Level Greater Than or Equal to a 2-fold-rise at Day 14 Compared to Baseline — 27…
Phase 1 N=18 Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 270.31; 248.46 ng / ml